- Home
- REFR vs ANTX Comparison
REFR vs ANTX Comparison
Compare REFR & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFR
- ANTX
- Stock Information
- Founded
- REFR 1965
- ANTX 2017
- Country
- REFR United States
- ANTX United States
- Employees
- REFR N/A
- ANTX N/A
- Industry
- REFR Multi-Sector Companies
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- REFR Miscellaneous
- ANTX Health Care
- Exchange
- REFR Nasdaq
- ANTX Nasdaq
- Market Cap
- REFR 48.3M
- ANTX 43.6M
- IPO Year
- REFR N/A
- ANTX 2022
- Fundamental
- Price
- REFR $1.20
- ANTX $1.50
- Analyst Decision
- REFR
- ANTX Hold
- Analyst Count
- REFR 0
- ANTX 5
- Target Price
- REFR N/A
- ANTX $3.50
- AVG Volume (30 Days)
- REFR 30.5K
- ANTX 120.7K
- Earning Date
- REFR 03-06-2025
- ANTX 03-25-2025
- Dividend Yield
- REFR N/A
- ANTX N/A
- EPS Growth
- REFR N/A
- ANTX N/A
- EPS
- REFR N/A
- ANTX N/A
- Revenue
- REFR $1,335,531.00
- ANTX N/A
- Revenue This Year
- REFR N/A
- ANTX N/A
- Revenue Next Year
- REFR N/A
- ANTX N/A
- P/E Ratio
- REFR N/A
- ANTX N/A
- Revenue Growth
- REFR 46.83
- ANTX N/A
- 52 Week Low
- REFR $1.10
- ANTX $0.87
- 52 Week High
- REFR $2.41
- ANTX $3.88
- Technical
- Relative Strength Index (RSI)
- REFR 38.51
- ANTX 77.32
- Support Level
- REFR $1.10
- ANTX $1.37
- Resistance Level
- REFR $1.42
- ANTX $1.52
- Average True Range (ATR)
- REFR 0.08
- ANTX 0.06
- MACD
- REFR -0.00
- ANTX 0.02
- Stochastic Oscillator
- REFR 31.43
- ANTX 95.32
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. Its revenue source comes from the licensing of technology.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.